Myriad Genetics (MYGN) 34.03 $MYGN
Myriad Genetics Earnings: Correction Offers Excellent Investing Opportunity
Andy Batts - at Seeking Alpha - Tue Feb 10, 3:25PM CST
MYGN: 34.03 (+0.40)
Comparing America's 3 Largest Research Services Companies
Joseph Cafariello - at Seeking Alpha - Mon Feb 09, 1:02PM CST
MYGN: 34.03 (+0.40), INCR: 24.19 (-0.45), NRCIB: 35.75 (+1.95)
Seeking Alpha's Biotech Weekly: Questioning Gilead, MannKind To Market, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 06, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
SGYP: 2.98 (unch), BLUE: 90.70 (+0.93), ZIOP: 9.64 (-0.35), MYGN: 34.03 (+0.40), PSTI: 2.91 (+0.01), PFE: 34.64 (-0.23), XON: 39.30 (+1.05), TKMR: 21.45 (-0.22), ASPX: 65.76 (+2.76), MNKD: 7.00 (+0.02), HSP: 87.35 (unch), ZTS: 45.46 (-0.33), ANTM: 141.05 (-0.95), WMGI: 25.68 (+0.17), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), THOR: 40.01 (+0.54), TEVA: 56.77 (-0.58), ABBV: 58.05 (+1.00), SNY: 49.42 (+0.82), ARNA: 4.55 (+0.02)
Myriad Genetics to Present at the 2015 Leerink Global Healthcare Conference
GlobeNewswire - Fri Feb 06, 12:00PM CST
Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, president and CEO of Myriad Genetics, is scheduled to present at the Leerink Global Healthcare Conference at 1:00 p.m. Eastern on February 12, 2015, at the Waldorf Astoria in New York, New York.
MYGN: 34.03 (+0.40)
Nasdaq stocks posting largest percentage decreases
AP - Thu Feb 05, 12:21PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
SPLS: 16.86 (-0.22), PPSI: 9.09 (-0.26), GEOS: 19.15 (+0.02), MYGN: 34.03 (+0.40), ADEP: 6.93 (-0.30), PACB: 6.96 (-0.06), MTRX: 19.92 (+0.77), LAYN: 7.93 (+0.22), LFUS: 98.58 (+0.50), ACHN: 10.89 (-0.20), BNFT: 21.08 (+0.84), AIRT: 19.45 (+0.39), BIND: 6.06 (+0.21), POWL: 33.41 (+0.39), PLNR: 6.63 (-0.07)
Global Molecular Diagnostics in Infectious Disease Testing Overview Report: Infectious disease space is the most dominant and profitable sector of molecular diagnostics
M2 - Thu Feb 05, 3:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/b4g8s4/molecular) has announced the addition of the "Global Molecular Diagnostics in Infectious Disease Testing Overview Report: Infectious disease space is the most dominant and profitable sector of molecular diagnostics" report to their offering. Topics covered in this study include: 1) the existing and emerging technologies in the field, 2) the U.S. and global market size for molecular diagnostic products and 3) the profiles of companies that are focusing on the molecular diagnostic sector. The research examines drivers and restraints for sales growth, market share and technical trends. In addition, an in-depth analysis of the competitive situation of prominent market venders is provided with five-year sales forecasts. This publications report describes the specific segment of the in vitro diagnostics market known as molecular diagnostics testing for infectious disease. In the current medical diagnostics market, molecular diagnostics in infectious disease testing offers one of the most promising areas for growth and innovation. The confluence of breakthroughs in genomics and proteomics-along with the development of microarray devices to measure analytes in the blood-has led to this revolutionary market development. Specifically, molecular diagnostics offers the power of advanced analytical techniques to diagnose infectious diseases. Whereas before, the detection of many infectious agents was slow and expensive due to reliance upon culturing methods, researchers are now at the cusp of overcoming such limitations via the use of nucleic acid-mediated molecular diagnostics testing. Key Topics Covered: 1. Overview 2. Introduction to Molecular Diagnostics for Infectious Disease Testing 3. Infectious Disease Diagnostics Molecular Testing Market 4. Molecular Diagnostic Testing Technology for Infectious Disease Testing 5. Business 6. Reimbursement and Billing Landscape for Molecular Diagnostics Testing for Infectious Disease 7. Regulatory Requirements 8. Business Decisions using Molecular Diagnostic Tests in Infectious Disease Testing 9. Economics of Anti-Microbial Drug Resistance: The Persistent Need for Antibacterials 10. Company Profiles - Abbott Laboratories - AdvanDx - Affymetrix - Arcxis Biotechnologies - Asuragen, Inc. - AutoGenomics, Inc. - Becton, Dickinson and Company - bioM?rieux - bioTheranostics - Cepheid - EraGen Biosciences - GenMark Diagnostics, Inc. - Genomix Biotech - Gen-Probe, Inc. (now known as Hologic Gen-Probe) - Genomica S.A.U. - Illumina, Inc. - Life Technologies (Thermo Fisher Scientific) - Luminex Corp. - Mobidiag - Myconostica - Myriad Genetics, Inc. - Nanosphere - NorDiag ASA (The DiaSorin Group) - Qiagen N.V. - Quidel - Roche Diagnostics (Roche Ltd.) - Siemens AG - SIRS-Lab - TrovaGene - Veredus Laboratories - Veridex, LLC (Janssen Diagnostics, LLC) For more information visit http://www.researchandmarkets.com/research/b4g8s4/molecular
GNMK: 13.51 (+0.21), ABT: 46.09 (+0.87), MYGN: 34.03 (+0.40), AGMX: (), CPHD: 59.62 (+0.72), ILMN: 198.54 (+1.81), QGEN: 23.68 (-0.06), LMNX: 15.45 (+0.02)
Myriad Genetics Falls 9.18% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Wed Feb 04, 4:24PM CST
Myriad Genetics (NASDAQ:MYGN) traded in a range yesterday that spanned from a low of $31.86 to a high of $34.97. Yesterday, the shares fell 9.2%, which took the trading range below the 3-day low of $36.78 on volume of 5.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MYGN: 34.03 (+0.40)
After Yesterday's Decline of 9.18%, Myriad Genetics Offers Investors Better Value
Comtex SmarTrend(R) - Wed Feb 04, 4:24PM CST
Myriad Genetics (NASDAQ:MYGN) traded in a range yesterday that spanned from a low of $31.86 to a high of $34.97. Yesterday, the shares fell 9.2%, which took the trading range below the 3-day low of $36.78 on volume of 5.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MYGN: 34.03 (+0.40)
General Motors and Sony are big market movers
AP - Wed Feb 04, 3:38PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Wednesday on the New York Stock Exchange and the Nasdaq Stock Market:
SPLS: 16.86 (-0.22), MYGN: 34.03 (+0.40), GILD: 101.90 (+1.10), AMGN: 153.48 (+0.30), ODP: 9.59 (-0.02), CTSH: 60.23 (-0.05)
Myriad Genetics (MYGN) Stock Tumbling Today After Jefferies Price Target Reduction
at The Street - Wed Feb 04, 2:33PM CST
Shares of Myriad Genetics (MYGN) stock are down after Jefferies lowered the company's price target to $32 from $37.
MYGN: 34.03 (+0.40)
Myriad Genetics Q2 Earnings, Revenues Beat; Fall Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 8:58AM CST
Although Myriad's (MYGN) second-quarter fiscal 2015 results beat the Zacks Consensus Estimate on both the top and bottom line fronts, on a year-over-year basis, both the figures declined substantially.
ACAD: 34.21 (+0.37), MYGN: 34.03 (+0.40), OPHT: 51.11 (+0.12), PRTA: 22.89 (+0.13)
Premarket Gainers / Losers as if 9:10 am
Seeking Alpha - at Seeking Alpha - Wed Feb 04, 8:13AM CST
SPLS: 16.86 (-0.22), EXXI: 4.00 (+0.42), NES: 3.52 (+0.13), MYGN: 34.03 (+0.40), CALX: 8.65 (-0.03), OIBR: 2.49 (+0.34), SNE: 27.30 (+0.19), SDRL: 12.32 (-0.70), RL: 135.20 (-0.60), SJM: 113.89 (+1.50), GENE: 8.04 (+1.90), GDP: 3.58 (+0.29), CPRX: 3.36 (-0.10), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), CMG: 674.89 (+4.60), VGGL: 1.77 (-0.08), REXX: 5.08 (+0.13), SFUN: 6.74 (-0.01), ENTR: 2.92 (unch)
Ahead of the Bell: Myriad sinks after cutting 2015 forecast
By The Associated Press - AP - Wed Feb 04, 8:01AM CST
Shares of Myriad Genetics plunged Wednesday before markets opened and a day after the genetic test maker chopped its fiscal year forecast due to reimbursement delays and announced the retirement of longstanding CEO Peter Meldrum.
MYGN: 34.03 (+0.40)
Myriad Genetics' (MYGN) CEO Peter Meldrum on Q2 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Feb 03, 9:53PM CST
MYGN: 34.03 (+0.40)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 4:37PM CST
CRMD: 3.27 (+0.02), TTWO: 28.40 (+0.96), MYGN: 34.03 (+0.40), BC: 55.30 (+0.61), CMG: 674.89 (+4.60), MXL: 8.37 (+0.09), WTW: 18.16 (+0.33), DWTI: 95.90 (-7.40), PLNR: 6.63 (-0.07), ENTR: 2.92 (unch)
Myriad -15.9%; CEO retiring, guidance light
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 4:11PM CST
MYGN: 34.03 (+0.40)
Myriad beats Street 2Q forecasts
Automated Insights - Tue Feb 03, 3:36PM CST
SALT LAKE CITY (AP) _ Myriad Genetics Inc. (MYGN) on Tuesday reported fiscal second-quarter profit of $24 million.
MYGN: 34.03 (+0.40)
Myriad Genetics (MYGN) Q2 2015 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Feb 03, 3:25PM CST
MYGN: 34.03 (+0.40)
Myriad Announces Retirement of Peter D. Meldrum, President and CEO
GlobeNewswire - Tue Feb 03, 3:18PM CST
Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that Peter D. Meldrum, president and chief executive officer, has notified the company of his decision to retire at the conclusion of the fiscal year on June 30, 2015. Pursuant to the company's succession plan, the board of directors has unanimously elected Mark C. Capone, currently president of Myriad Genetic Laboratories, Inc., as Mr. Meldrum's successor. Mr. Capone, a 13-year veteran of the company, has worked closely with Mr. Meldrum and the board in charting the strategic direction and managing the overall business of the company, as well as regularly interfacing with our institutional shareholders.
MYGN: 34.03 (+0.40)
Myriad Genetics Reports Fiscal Second-Quarter 2015 Financial Results
GlobeNewswire - Tue Feb 03, 3:18PM CST
-- Revenues of $184.4 Million
MYGN: 34.03 (+0.40)
Myriad Genetics Earnings: Correction Offers Excellent Investing Opportunity
Andy Batts - at Seeking Alpha - Tue Feb 10, 3:25PM CST
MYGN: 34.03 (+0.40)
Comparing America's 3 Largest Research Services Companies
Joseph Cafariello - at Seeking Alpha - Mon Feb 09, 1:02PM CST
MYGN: 34.03 (+0.40), INCR: 24.19 (-0.45), NRCIB: 35.75 (+1.95)
Seeking Alpha's Biotech Weekly: Questioning Gilead, MannKind To Market, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 06, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
SGYP: 2.98 (unch), BLUE: 90.70 (+0.93), ZIOP: 9.64 (-0.35), MYGN: 34.03 (+0.40), PSTI: 2.91 (+0.01), PFE: 34.64 (-0.23), XON: 39.30 (+1.05), TKMR: 21.45 (-0.22), ASPX: 65.76 (+2.76), MNKD: 7.00 (+0.02), HSP: 87.35 (unch), ZTS: 45.46 (-0.33), ANTM: 141.05 (-0.95), WMGI: 25.68 (+0.17), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), THOR: 40.01 (+0.54), TEVA: 56.77 (-0.58), ABBV: 58.05 (+1.00), SNY: 49.42 (+0.82), ARNA: 4.55 (+0.02)
Myriad Genetics to Present at the 2015 Leerink Global Healthcare Conference
GlobeNewswire - Fri Feb 06, 12:00PM CST
Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, president and CEO of Myriad Genetics, is scheduled to present at the Leerink Global Healthcare Conference at 1:00 p.m. Eastern on February 12, 2015, at the Waldorf Astoria in New York, New York.
MYGN: 34.03 (+0.40)
Nasdaq stocks posting largest percentage decreases
AP - Thu Feb 05, 12:21PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
SPLS: 16.86 (-0.22), PPSI: 9.09 (-0.26), GEOS: 19.15 (+0.02), MYGN: 34.03 (+0.40), ADEP: 6.93 (-0.30), PACB: 6.96 (-0.06), MTRX: 19.92 (+0.77), LAYN: 7.93 (+0.22), LFUS: 98.58 (+0.50), ACHN: 10.89 (-0.20), BNFT: 21.08 (+0.84), AIRT: 19.45 (+0.39), BIND: 6.06 (+0.21), POWL: 33.41 (+0.39), PLNR: 6.63 (-0.07)
Global Molecular Diagnostics in Infectious Disease Testing Overview Report: Infectious disease space is the most dominant and profitable sector of molecular diagnostics
M2 - Thu Feb 05, 3:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/b4g8s4/molecular) has announced the addition of the "Global Molecular Diagnostics in Infectious Disease Testing Overview Report: Infectious disease space is the most dominant and profitable sector of molecular diagnostics" report to their offering. Topics covered in this study include: 1) the existing and emerging technologies in the field, 2) the U.S. and global market size for molecular diagnostic products and 3) the profiles of companies that are focusing on the molecular diagnostic sector. The research examines drivers and restraints for sales growth, market share and technical trends. In addition, an in-depth analysis of the competitive situation of prominent market venders is provided with five-year sales forecasts. This publications report describes the specific segment of the in vitro diagnostics market known as molecular diagnostics testing for infectious disease. In the current medical diagnostics market, molecular diagnostics in infectious disease testing offers one of the most promising areas for growth and innovation. The confluence of breakthroughs in genomics and proteomics-along with the development of microarray devices to measure analytes in the blood-has led to this revolutionary market development. Specifically, molecular diagnostics offers the power of advanced analytical techniques to diagnose infectious diseases. Whereas before, the detection of many infectious agents was slow and expensive due to reliance upon culturing methods, researchers are now at the cusp of overcoming such limitations via the use of nucleic acid-mediated molecular diagnostics testing. Key Topics Covered: 1. Overview 2. Introduction to Molecular Diagnostics for Infectious Disease Testing 3. Infectious Disease Diagnostics Molecular Testing Market 4. Molecular Diagnostic Testing Technology for Infectious Disease Testing 5. Business 6. Reimbursement and Billing Landscape for Molecular Diagnostics Testing for Infectious Disease 7. Regulatory Requirements 8. Business Decisions using Molecular Diagnostic Tests in Infectious Disease Testing 9. Economics of Anti-Microbial Drug Resistance: The Persistent Need for Antibacterials 10. Company Profiles - Abbott Laboratories - AdvanDx - Affymetrix - Arcxis Biotechnologies - Asuragen, Inc. - AutoGenomics, Inc. - Becton, Dickinson and Company - bioM?rieux - bioTheranostics - Cepheid - EraGen Biosciences - GenMark Diagnostics, Inc. - Genomix Biotech - Gen-Probe, Inc. (now known as Hologic Gen-Probe) - Genomica S.A.U. - Illumina, Inc. - Life Technologies (Thermo Fisher Scientific) - Luminex Corp. - Mobidiag - Myconostica - Myriad Genetics, Inc. - Nanosphere - NorDiag ASA (The DiaSorin Group) - Qiagen N.V. - Quidel - Roche Diagnostics (Roche Ltd.) - Siemens AG - SIRS-Lab - TrovaGene - Veredus Laboratories - Veridex, LLC (Janssen Diagnostics, LLC) For more information visit http://www.researchandmarkets.com/research/b4g8s4/molecular
GNMK: 13.51 (+0.21), ABT: 46.09 (+0.87), MYGN: 34.03 (+0.40), AGMX: (), CPHD: 59.62 (+0.72), ILMN: 198.54 (+1.81), QGEN: 23.68 (-0.06), LMNX: 15.45 (+0.02)
Myriad Genetics Falls 9.18% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Wed Feb 04, 4:24PM CST
Myriad Genetics (NASDAQ:MYGN) traded in a range yesterday that spanned from a low of $31.86 to a high of $34.97. Yesterday, the shares fell 9.2%, which took the trading range below the 3-day low of $36.78 on volume of 5.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MYGN: 34.03 (+0.40)
After Yesterday's Decline of 9.18%, Myriad Genetics Offers Investors Better Value
Comtex SmarTrend(R) - Wed Feb 04, 4:24PM CST
Myriad Genetics (NASDAQ:MYGN) traded in a range yesterday that spanned from a low of $31.86 to a high of $34.97. Yesterday, the shares fell 9.2%, which took the trading range below the 3-day low of $36.78 on volume of 5.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MYGN: 34.03 (+0.40)
General Motors and Sony are big market movers
AP - Wed Feb 04, 3:38PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Wednesday on the New York Stock Exchange and the Nasdaq Stock Market:
SPLS: 16.86 (-0.22), MYGN: 34.03 (+0.40), GILD: 101.90 (+1.10), AMGN: 153.48 (+0.30), ODP: 9.59 (-0.02), CTSH: 60.23 (-0.05)
Myriad Genetics (MYGN) Stock Tumbling Today After Jefferies Price Target Reduction
at The Street - Wed Feb 04, 2:33PM CST
Shares of Myriad Genetics (MYGN) stock are down after Jefferies lowered the company's price target to $32 from $37.
MYGN: 34.03 (+0.40)
Myriad Genetics Q2 Earnings, Revenues Beat; Fall Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 8:58AM CST
Although Myriad's (MYGN) second-quarter fiscal 2015 results beat the Zacks Consensus Estimate on both the top and bottom line fronts, on a year-over-year basis, both the figures declined substantially.
ACAD: 34.21 (+0.37), MYGN: 34.03 (+0.40), OPHT: 51.11 (+0.12), PRTA: 22.89 (+0.13)
Premarket Gainers / Losers as if 9:10 am
Seeking Alpha - at Seeking Alpha - Wed Feb 04, 8:13AM CST
SPLS: 16.86 (-0.22), EXXI: 4.00 (+0.42), NES: 3.52 (+0.13), MYGN: 34.03 (+0.40), CALX: 8.65 (-0.03), OIBR: 2.49 (+0.34), SNE: 27.30 (+0.19), SDRL: 12.32 (-0.70), RL: 135.20 (-0.60), SJM: 113.89 (+1.50), GENE: 8.04 (+1.90), GDP: 3.58 (+0.29), CPRX: 3.36 (-0.10), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), CMG: 674.89 (+4.60), VGGL: 1.77 (-0.08), REXX: 5.08 (+0.13), SFUN: 6.74 (-0.01), ENTR: 2.92 (unch)
Ahead of the Bell: Myriad sinks after cutting 2015 forecast
By The Associated Press - AP - Wed Feb 04, 8:01AM CST
Shares of Myriad Genetics plunged Wednesday before markets opened and a day after the genetic test maker chopped its fiscal year forecast due to reimbursement delays and announced the retirement of longstanding CEO Peter Meldrum.
MYGN: 34.03 (+0.40)
Myriad Genetics' (MYGN) CEO Peter Meldrum on Q2 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Feb 03, 9:53PM CST
MYGN: 34.03 (+0.40)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 4:37PM CST
CRMD: 3.27 (+0.02), TTWO: 28.40 (+0.96), MYGN: 34.03 (+0.40), BC: 55.30 (+0.61), CMG: 674.89 (+4.60), MXL: 8.37 (+0.09), WTW: 18.16 (+0.33), DWTI: 95.90 (-7.40), PLNR: 6.63 (-0.07), ENTR: 2.92 (unch)
Myriad -15.9%; CEO retiring, guidance light
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 4:11PM CST
MYGN: 34.03 (+0.40)
Myriad beats Street 2Q forecasts
Automated Insights - Tue Feb 03, 3:36PM CST
SALT LAKE CITY (AP) _ Myriad Genetics Inc. (MYGN) on Tuesday reported fiscal second-quarter profit of $24 million.
MYGN: 34.03 (+0.40)
Myriad Genetics (MYGN) Q2 2015 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Feb 03, 3:25PM CST
MYGN: 34.03 (+0.40)
Myriad Announces Retirement of Peter D. Meldrum, President and CEO
GlobeNewswire - Tue Feb 03, 3:18PM CST
Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that Peter D. Meldrum, president and chief executive officer, has notified the company of his decision to retire at the conclusion of the fiscal year on June 30, 2015. Pursuant to the company's succession plan, the board of directors has unanimously elected Mark C. Capone, currently president of Myriad Genetic Laboratories, Inc., as Mr. Meldrum's successor. Mr. Capone, a 13-year veteran of the company, has worked closely with Mr. Meldrum and the board in charting the strategic direction and managing the overall business of the company, as well as regularly interfacing with our institutional shareholders.
MYGN: 34.03 (+0.40)
Myriad Genetics Reports Fiscal Second-Quarter 2015 Financial Results
GlobeNewswire - Tue Feb 03, 3:18PM CST
-- Revenues of $184.4 Million
MYGN: 34.03 (+0.40)
